Statins in clinical medicine

Area of Science:

• Cardiology
• Pharmacology
• Preventive Medicine

Background:

• Statins inhibit cholesterol biosynthesis, primarily reducing low-density lipoprotein (LDL) cholesterol.
• This reduction correlates with a significant decrease in major vascular events and coronary mortality.
• The cost-effectiveness of statins for primary prevention is debated, necessitating individualized risk assessment.

Purpose of the Study:

• To review the efficacy and safety of statin therapy in cardiovascular disease prevention.
• To discuss the role of statins in primary versus secondary prevention, particularly in patients with diabetes.
• To evaluate the benefits and risks of statin therapy, including pleiotropic effects and potential side effects.

Main Methods:

• Review of randomized controlled trials and meta-analyses on statin therapy.
• Analysis of LDL cholesterol reduction and its impact on vascular events.
• Consideration of patient-specific factors, cardiovascular risk calculators, and guidelines for statin use.

Main Results:

• Statins achieve approximately a 20% relative reduction in vascular events per mmol/L LDL reduction.
• Statin therapy is generally indicated for patients with diabetes due to their high cardiovascular risk.
• Statins are well-tolerated and safe when appropriate precautions are taken; ezetimibe can be added if needed.
• The vascular benefits of statins outweigh the small risk of incident diabetes mellitus.

Conclusions:

• Statin therapy is a cornerstone in cardiovascular risk reduction, with benefits extending beyond LDL cholesterol lowering.
• Individualized treatment strategies, considering patient risk and tolerance, are essential for optimal statin use.
• While statins have pleiotropic effects, their primary benefit stems from LDL cholesterol reduction.